SER 109

Drug Profile

SER 109

Alternative Names: SER109

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Anti-infectives; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium-difficile-infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium-difficile-infections

Most Recent Events

  • 09 Nov 2017 Health Canada clears clinical trial application for phase III ECOSPOR III study
  • 04 Oct 2017 Pooled efficacy data from phase Ib and phase II studies in Clostridium difficile infections presented at the IDWeek 2017 (iDW-2017)
  • 12 Jun 2017 The US FDA designates ECOSPOR III trial a phase III trial for Clostridium difficile infections (Recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top